1Emery P. The Dunlop-Dottridge Lecture: progrosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J Rheumatol,1997,24:1436-1442.
2Tugwel P, Ortiz ZB. Rheumatoid arthritis: emerging evidence for the benefits of early and aggressive therapy. Disease Manage Health Outcomes, 1997,3:141-153.
3Felson DT, Anderson JJ, Boers M, et al. The American college of Rheumatoid preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum, 1993,36 :729-740.
4Egger MJ, Huth DA, Ward JR, et al. Reduced joint count indices in the evaluation of rheumatoid arthritis. Arthritis & Rheum ,1985,28:613-619.
5Choi HK, Hernan MA, Seeger JD, et al Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.Lancet,2002, 359:1173-1177.
6Pincus T, Callahan LF. The side effects of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol, 1993,32 (Suppl 1):S28-S32.
7Maarten B. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis & Rheum, 2003,48: 1771-1774.
8O′Dell JR, Blakely KW, Mallek JA, et al. Treatment of early seropositive rheumatoid arthritis. A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis & Rheum, 2001; 44:2235-2241.
同被引文献9
1Mc Innes I B,Schett G.The pathogenesis of rheumatoid arthritis[J].New England Journal of Medicine,2011,365(23):2205-2219.
2Rodríguez-Rodríguez L,González-Juanatey C,Palomino-Morales R,et al.TNFA-308(rs1800629)polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis[J].Atherosclerosis,2011,216(1):125-130.
3Bohanec Grabar P,Leandro-García L J,Inglada-Pérez L,et al.Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients[J].Pharmacogenomi cs,2012,13(14):1583-1594.
4Bakker M F,Jacobs J W G,Welsing P M J,et al.Low-dose prednisone inclusion in a methotrexate-based,tight control strategy for early rheumatoid arthritis:a randomized trial[J].Annals of Internal Medicine,2012,156(5):329-339.
5Cui J,Stahl E A,Saevarsdottir S,et al.Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis[J].PLo S genetics,2013,9(3):e1003394.
